Redeye provides a research update following the Q4 2023 report from Fragbite Group.
Redeye provides a research update on Smart Eye following the Q4 2023 report.
Redeye provides an update in relation to CLS’ Q4 2023 report.
Redeye saw a report with softer sales and results than we expected.
Scanfil's Q4 net sales were in line with LSEG Data & Analytics consensus but the midpoint of the com...
Potential for transformative design wins in next 12 months We forecast 40% revenue CAGR '24e-'26e If...
'24e-'25e adj. EBIT down 5-3% Successfully reducing excess working capital '24e-'25e EV/EBIT of 37x-...
Redeye hosted Smart Eye for a Live Q. Management of Smart Eye presented the company’s quarterly repo...
Clear signs of scalability in solid report Sensys Gatso reported a solid Q4(23).
We expect 16% EBITA growth in 2024 from better market & scale Estimates down on European miss and FX...
Redeye leaves its estimates and valuation untouched following the report.
IRLAB Therapeutics reported positive feedback from its FDA end-of-Phase II (EoP2) meeting earlier in...
The company’s publishing title continued to uphold the new level of sales that have been reported si...
Maven Wireless publicerade den 23 februari år 2024 koncernens delårsrapport för det fjärde kvartalet...
Redeye updates on Northbaze following Q4 results, which were weaker than expected on the topline but...
Redeye comments on Cantargia's Q4 report, which contains progress with CAN10 and with nadunolimab in...
Avslutar året med ett rekordkvartal Nettoomsättningen i kvartalet uppgick till 768 mkr, vilket motsv...
Rapportkommentar, Q4 Guards rapport för det fjärde kvartalet innehöll inga överraskningar.
Redeye provides a research update following the Q4 report published by Initiator Pharma earlier toda...
Tessin, med en digital investeringsplattform för säkerställda fastighetslån, uppvisade totala intäkt...
